LAWRENCEVILLE, N.J., Nov. 10 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced results of a recent survey of ophthalmologists regarding issues in the treatment of moderate to severe cases of dry eye. Aton provides the dry eye medication Lacrisert(R) (hydroxypropyl cellulose ophthalmic insert), a preservative-free, once-daily*, sustained release prescription insert that helps to retain moisture, stabilize the tear film, and lubricate the eye.
Nearly all of the ophthalmologists surveyed (94%) believe more treatment options are needed for moderate to severe dry eye. While 80% feel current therapies are effective for mild dry eye, only 33% feel they are effective for moderate dry eye and 67% feel they are only somewhat effective or not very effective. Only 5% feel current therapies are effective for severe dry eye, while 56% feel they are somewhat effective and 38%, not very or not at all effective.
"Ophthalmologists are still looking for more effective therapies for treating moderate to severe dry eye," commented Dr. Penny Asbell, Professor, Department of Ophthalmology, Mount Sinai School of Medicine; Director, Cornea Services and Refractive Surgery Center, New York; and co-author of the pivotal textbook 'Dry Eye Disease, the Clinician's Guide to Diagnosis and Treatment.' "Nearly all ophthalmologists want more treatment options for these more serious cases." Dr. Asbell is a member of Aton Pharma's Scientific Advisory Board.
"We are proud to be working with Dr. Asbell to contribute to eye care professionals' insights about the state of the art of treatment of dry eye," stated Michael G. Wells, Chief Executive Officer of Aton Pharma. "Ophthalmology is one of the important markets Aton serves as a diversified specialty pharmaceutical company providing medically essential therapies to patients around the world."
Treatment Approaches and Options
The survey respondents reported that over the
|SOURCE Aton Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved